trenbolone enanthate

Suspension for intramuscular and subcutaneous administration.

Auxiliary components:. Buffered saline (sodium chloride, potassium chloride, sodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate, water for injections) – 0.5 mL

of strains the vaccine meets the WHO recommendations for the EU’s Northern Hemisphere and the decision on the composition of influenza vaccines season 2008/2009 gg.
VAXIGRIP may contain no more than 0.05 micrograms trenbolone enanthate of ovalbumin in 1 dose.

DESCRIPTION
Low opalestsirukschaya slightly whitish liquid.

Immunobiological properties
VAXIGRIP forms the development of specific immunity to epidemiologically relevant strains of influenza virus types A and B contained in the vaccine. Immunity is developed between the 2nd and 3rd weeks after vaccination and lasts for 6 to 12 months.

PURPOSE
Prophylaxis of influenza in adults and children 6 months of age. Vaccination is particularly indicated persons at increased risk of associated complications.

CONTRAINDICATIONS
Hypersensitivity to any component of the vaccine, as well as components of chicken or chicken eggs, neomycin, formaldehyde and octoxynol-9.
In diseases accompanied by fever, as well as in acute exacerbation of chronic disease or vaccination should be delayed until recovery.

Use during pregnancy and lactation
The available data on the use of the vaccine in pregnant women do not indicate the possibility of a negative impact of vaccination on the fetus and the woman’s body. Vaccination trenbolone enanthate with this drug may be carried out starting from the second trimester of pregnancy. For medical reasons, if there is an increased risk of associated complications, the use of the vaccine is recommended, regardless of the gestational age.
The vaccine can be used during breastfeeding.

DOSAGE AND ADMINISTRATION
The vaccine is administered by intramuscular or deep subcutaneous injection. Do not inject intravenously! Before use, the vaccine should be kept at room temperature and shake.

Dosage: for children over 36 months and adults – 0.5 ml dose; for children aged from 6 months to 35 months inclusive – 0.25 ml dose.

Children under 9 years old, the first to be vaccinated against influenza, shown twice VAXIGRIP administration at intervals of 4 weeks. When using a syringe containing 0.5 ml of a vaccine for immunization of children, which shows the introduction of 0.25 ml dose, half the contents must be removed by pushing the plunger to special risks. Enter patient remaining amount of the vaccine.

When using a vial containing 0.5 ml of the vaccine for immunization of children, which shows the introduction of 0.25 ml dose, it must be picked up using a syringe imeyutsego sootvetstvuyutsuyu grading.The balance of the vaccine vial should be immediately destroyed.

SIDE EFFECTS
In clinical studies are usually observed (with a frequency of 1/100 to 1/10):
General reactions: fever, malaise, shivering, fatigue, headache, sweating, muscle pain (myalgia), joint pain ( arthralgia).
Local reactions:. redness, swelling, pain, bruising (ecchymosis), induration at the injection site
. These reactions trenbolone enanthate usually disappear within 1-2 days and not trebukt special treatment
during mass application VAXIGRIP in very rare cases, adverse reactions occurred sledukschie :

From the circulatory and lymphatic systems: transient thrombocytopenia, lymphadenopathy, vasculitis with possible short-term involvement of the kidneys (in rare cases)
the nervous system: paresthesia, Guillain-Barre syndrome, neuritis, neuralgia, convulsions, encephalomyelitis;
Allergic reactions: rash, itching, skin rashes; dyspnea, angioedema, shock.

SPECIAL INSTRUCTIONS
Due to the fact that the incidence of influenza is seasonal in nature, it is recommended annually vaktsinatsiyuv autumn and winter, when flu risk is maximal.
The vaccine leads to the development of immunity only against 3 influenza virus strains contained in the product or against strains similar to those indicated. VAXIGRIP does not trenbolone enanthate provide immunity against the formation of influenza vaccination in the incubation period of the disease, as well as against influenza caused by other strains of the virus. VAXIGRIP not generate the development of immunity against diseases of similar symptoms with the flu, but caused by other pathogens. Vaccination against influenza, carried out during the previous epidemic season, can not provide reliable protection for the next season, because for each epidemic season is characterized by its most common strains of influenza virus.
The doctor should be informed of the presence of the patient immunodeficiency, allergy or unusual reactions to previous vaccinations as well as any treatment to coincide with the vaccination or previous vaccination.
The vaccine should not be used in uncharacteristic coloring suspension or the presence of foreign particles in it.
The use of this vaccine does not affect the ability to drive a motor vehicle or other machinery.
The doctor should be informed about all the cases of adverse reactions, not limited to those listed in these instructions. Within a few days after vaccination may be instances of false positives in the determination of antibodies to HIV-1, hepatitis C and, particularly, human T-lymphotropic virus type 1 enzyme immunoassay (EIA) method. In these cases, the evaluation result obtained by ELISA, performed by Western blotting. When vaccination must be available medicines needed to provide emergency assistance in case of an anaphylactic reaction.

INTERACTION WITH OTHER DRUGS
VAXIGRIP can be used simultaneously (in one day) with other vaccines. Thus drugs must be administered at different sites using various syringes. The vaccine can be mixed with any other drug in the syringe. Patients undergoing immunosuppressive therapy (corticosteroids, cytotoxic drugs or radioactive), the immune response trenbolone enanthate after vaccination may be insufficient.

PACKAGING
In 0.5 ml of vaccine into the syringe, the syringe 1 in a closed cellular packaging, in a closed cellular packaging 1 with the instruction primeneniyuv carton box.
In 0.5 ml vaccine ampoule of 10 vials in blisters, 2 blisters (20 vials) with instructions for primeneniyuv carton box.

SHELF LIFE
12 months. The date of the expiration date is considered to be the last day of the month indicated on the package.
Do not use after the expiration date printed on the package. steroiden kaufen

steroide kaufen deutschland

anabolika steroide kaufen bodybuilding shakeology bruce lee workout bodybuilding weight loss diet